Literature DB >> 27899169

Is It Time to Incorporate the Left Atrial Size to the Current Stroke Risk Scoring Systems for Atrial Fibrillation?.

Jonathan D Gardner, William Paul Skelton, Rami N Khouzam.   

Abstract

Primary care physicians and cardiologists rely on risk scoring systems, which consist of a number of clinical variables used together, to predict stroke risk in patients with atrial fibrillation (AF). Ultimately, this helps in determining the need for anticoagulation. Left atrial size is not used in any stroke risk scoring system to stratify patients at risk for cardioembolic stroke. Throughout the literature, there is much debate surrounding the use of left atrial size as an additional risk factor for stroke in patients with and without AF. This review summarizes the stroke risk scoring systems in the currently available literature and the increasing risk of stroke associated with left atrial size. In conclusion, the authors propose the consideration of a tool to incorporate both the best available stroke risk scoring systems and the left atrial size, for a better risk assessment and management of AF. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27899169     DOI: 10.1016/j.cpcardiol.2016.10.004

Source DB:  PubMed          Journal:  Curr Probl Cardiol        ISSN: 0146-2806            Impact factor:   5.200


  3 in total

Review 1.  Population-Based Screening for Atrial Fibrillation.

Authors:  Shaan Khurshid; Jeffrey S Healey; William F McIntyre; Steven A Lubitz
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

Review 2.  Can echocardiography improve the prediction of thromboembolic risk in atrial fibrillation? Evidences and perspectives.

Authors:  Antonella Tufano; Maurizio Galderisi
Journal:  Intern Emerg Med       Date:  2020-03-02       Impact factor: 3.397

3.  Safety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab.

Authors:  Gian Galeazzo Riario Sforza; Francesco Gentile; Fabio Stock; Francesco Caggiano; Enrica Chiocca; Cristoforo Incorvaia
Journal:  SAGE Open Med Case Rep       Date:  2018-01-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.